{
    "pmcid": "9016159",
    "qa_pairs": {
        "How can nanobodies enhance their neutralizing potency and breadth against SARS-CoV-2 variants?": [
            "By targeting multiple sites on the spike protein",
            "By increasing their size to cover more surface area",
            "By binding to the ACE2 receptor instead of the spike protein",
            "By incorporating mutations that mimic viral variants"
        ],
        "What advantage do nanobodies have over conventional antibodies in targeting the SARS-CoV-2 spike protein?": [
            "They can access cryptic epitopes hidden from larger antibodies",
            "They have a higher affinity for the ACE2 receptor",
            "They are less likely to induce immune escape",
            "They can directly cleave the spike protein"
        ],
        "What is one potential therapeutic application of nanobodies in the context of COVID-19?": [
            "Used as prophylactic agents to prevent infection",
            "Used to enhance the immune response to vaccines",
            "Used to directly degrade viral RNA",
            "Used to replace ACE2 receptors on host cells"
        ],
        "What is the primary role of the S1 subunit of the SARS-CoV-2 spike protein?": [
            "Responsible for receptor binding",
            "Facilitates membrane fusion",
            "Forms a trimeric crown on the virus surface",
            "Activates host proteases like TMPRSS2"
        ],
        "Which host receptor does the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein specifically interact with?": [
            "Angiotensin-converting enzyme 2 (ACE2)",
            "Dipeptidyl peptidase-4 (DPP4)",
            "Cluster of differentiation 4 (CD4)",
            "Feline aminopeptidase N (fAPN)"
        ]
    }
}